References
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 2021;71(3):209–249. [cited 2023 Oct 31]. Available from: https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21660
- Van Cott C. Cancer genetics. Surg Clin North Am. 2020;100(3):483–498. doi: 10.1016/j.suc.2020.02.012
- Boussios S, Mikropoulos C, Samartzis E, et al. Wise management of ovarian cancer: on the cutting edge. J Pers Med [Internet]. 2020 [cited 2023 Dec 30];10(2):1–20. PMC7354604/
- Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708
- Aliyuda F, Moschetta M, Ghose A, et al. Advances in ovarian cancer treatment beyond PARP inhibitors. Curr Cancer Drug Targets [Internet]. 2023;23(6):433–446. [cited 2023 Dec 30]. Available from: https://pubmed.ncbi.nlm.nih.gov/36757037/
- Pavlidis N, Rassy E, Vermorken JB, et al. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiol [Internet]. 2021;75:102045. [cited 2023 Dec 30]. Available from: https://pubmed.ncbi.nlm.nih.gov/34638085/
- Boussios S, Moschetta M, Zarkavelis G, et al. Ovarian sex-cord stromal tumours and small cell tumours: pathological, genetic and management aspects. Crit Rev Oncol Hematol. 2017;120:43–51. doi: 10.1016/j.critrevonc.2017.10.007
- Boussios S, Zarkavelis G, Seraj E, et al. Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies. Anticancer Res [Internet]. 2016;36(10):5031–5042. [cited 2023 Dec 31]. Available from: https://pubmed.ncbi.nlm.nih.gov/27798862/
- Lee Y-C, Lee Y-L, Li C-Y. BRCA genes and related cancers: a meta-analysis from epidemiological cohort studies. Switzerland: Medicina (Kaunas). 2021.
- Katsuki Y, Jeggo PA, Uchihara Y, et al. DNA double-strand break end resection: a critical relay point for determining the pathway of repair and signaling. Genome Instab Dis [Internet]. 2020;1(4):155–171. [cited 2023 Dec 30]. Available from: https://link.springer.com/article/10.1007/s42764-020-00017-8
- Boussios S, Rassy E, Moschetta M, et al. BRCA mutations in ovarian and prostate cancer: bench to bedside. Cancers (Basel) [Internet]. 2022;14(16):3888. [cited 2023 Dec 30]. Available from: https://pubmed.ncbi.nlm.nih.gov/36010882/
- Boussios S, Moschetta M, Karihtala P, et al. Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis? Ann Transl Med [Internet]. 2020;8:1706–1706. [cited 2023 Dec 30]. Available from: /pmc/articles/PMC7812175/
- Chen A. PARP inhibitors: its role in treatment of cancer. Chin J Cancer. 2011;30:463–471. doi: 10.5732/cjc.011.10111
- Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A. 2011;108(8):3406–3411. doi: 10.1073/pnas.1013715108
- Zheng F, Zhang Y, Chen S, et al. Mechanism and current progress of poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Biomed Pharmacother. 2020;123:109661. doi: 10.1016/j.biopha.2019.109661
- Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3):193–204. doi: 10.1038/nrc2342
- Konstantinopoulos PA, Ceccaldi R, Shapiro GI, et al. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian Cancer. Cancer Discov. 2015;5(11):1137–1154. doi: 10.1158/2159-8290.CD-15-0714
- Clark JB, Ferris GM, Pinder S. Inhibition of nuclear NAD nucleosidase and poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5′-methyl nicotinamide. Biochim Biophys Acta. 1971;238(1):82–85. doi: 10.1016/0005-2787(71)90012-8
- Talazoparib - brand name list from Drugs.com [Internet]. [cited 2023 Oct 29]. Available from: https://www.drugs.com/ingredient/talazoparib.html
- Olaparib - brand name list from Drugs.com [Internet]. [cited 2023 Oct 29]. Available from: https://www.drugs.com/ingredient/olaparib.html
- Drugs.com. Niraparib - brand name list from Drugs.com.
- Rucaparib - brand name list from Drugs.com [Internet]. [cited 2023 Oct 29]. Available from: https://www.drugs.com/ingredient/rucaparib.html
- Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 2020;34(5–6):360–394. doi: 10.1101/gad.334516.119
- Valabrega G, Scotto G, Tuninetti V, et al. Differences in PARP inhibitors for the treatment of ovarian cancer: mechanisms of action, pharmacology, safety, and efficacy. Int J Mol Sci. 2021;22(8):22. doi: 10.3390/ijms22084203
- Kujawa KA, Lisowska KM. Ovarian cancer–from biology to clinic. Postepy Higieny i Medycyny Doswiadczalnej. 2015;69:1275–1290. doi: 10.5604/17322693.1184451
- Laganà AS, Colonese F, Colonese E, et al. Cytogenetic analysis of epithelial ovarian cancer’s stem cells: an overview on new diagnostic and therapeutic perspectives. Eur J Gynaecol Oncol. 2015;36:495–505. doi: 10.1155/2015/986281
- Ghose A, Gullapalli SVN, Chohan N, et al. Applications of proteomics in ovarian cancer: dawn of a new era. Proteomes [Internet]. 2022;10:16. [cited 2023 Dec 30]. Available from: https://www.mdpi.com/2227-7382/10/2/16/htm
- Caruso G, Tomao F, Parma G, et al. Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions. Int J Gynecol Cancer [Internet]. 2023;33(4):431–443. [cited 2023 Dec 30]. Available from: https://pubmed.ncbi.nlm.nih.gov/36928097/
- Musella A, Vertechy L, Romito A, et al. Bevacizumab in ovarian cancer: state of the art and unanswered questions. Chemotherapy [Internet]. 2017;62(2):111–120. [cited 2023 Dec 30]. Available from: https://pubmed.ncbi.nlm.nih.gov/27794568/
- D’Augè TG, Giannini A, Bogani G, et al. Prevention, screening, treatment and follow-up of gynecological cancers: state of art and future perspectives. Clin Exp Obstet Gynecol [Internet]. 2023;50(8):160. [cited 2023 Dec 30]. Available from: https://www.imrpress.com/journal/CEOG/50/8/10.31083/j.ceog5008160/htm
- Grunewald T, Ledermann JA. Targeted therapies for ovarian cancer. Best pract res Clin Obstet Gynaecol. Best Pract Res Clin Obstet Gynaecol. 2017;41:139–152. doi: 10.1016/j.bpobgyn.2016.12.001
- Mittica G, Ghisoni E, Giannone G, et al. PARP inhibitors in ovarian Cancer. Recent Pat Anticancer Drug Discov. 2018;13(4):392–410. doi: 10.2174/1574892813666180305165256
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71
- Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. Cochrane Handbook Syst Rev Interv [Internet]. 2019:1–694. [cited 2023 Oct 29] Available from: https://onlinelibrary.wiley.com/doi/book/10.1002/9781119536604
- Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials [Internet]. 2007; 8(1). [cited 2023 Oct 29]. Available from: https://pubmed.ncbi.nlm.nih.gov/17555582/
- Clamp AR, Lorusso D, Oza AM, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase 3 trial ARIEL3. Int J Gynecol Cancer [Internet]. 2021;31(7):949. [cited 2023 Nov 2]. Available from: /pmc/articles/PMC9445915/
- Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet [Internet]. 2017;390(10106):1949–1961. [cited 2023 Nov 2]. Available from: https://pubmed.ncbi.nlm.nih.gov/28916367/
- Monk BJ, Parkinson C, Lim MC, et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45). JCO [Internet]. 2022;40(34):3952–3964. [cited 2023 Nov 2]. Available from: https://pubmed.ncbi.nlm.nih.gov/35658487/
- Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med [Internet]. 2023;388(8):719–732. [cited 2023 Nov 2]. Available from: https://pubmed.ncbi.nlm.nih.gov/36795891/
- Kristeleit R, Lisyanskaya A, Fedenko A, et al. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncol [Internet]. 2022;23(4):465–478. [cited 2023 Nov 2]. Available from: https://pubmed.ncbi.nlm.nih.gov/35298906/
- Al Hadidi S, Aburahma A, Badami S, et al. PARP (Poly(hypenCapswithspaceRetainColl1ibose) polymerase) inhibitors in platinum-sensitive recurrent ovarian cancer: a meta-analysis of randomized controlled trials. Oncol Res Treat. 2018;41(4):226–234. doi: 10.1159/000486418
- Staropoli N, Ciliberto D, Del Giudice T, et al. The era of PARP inhibitors in ovarian cancer: “class action” or not? A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018;131:83–89. doi: 10.1016/j.critrevonc.2018.08.011
- Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921. doi: 10.1038/nature03445
- Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–917. doi: 10.1038/nature03443
- Gu L, Du N, Jin Q, et al. Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: a meta-analysis. Crit Rev Oncol Hematol. 2020;147:102888. doi: 10.1016/j.critrevonc.2020.102888
- Hao J, Liu Y, Zhang T, et al. Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2021;157:103145. doi: 10.1016/j.critrevonc.2020.103145
- Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–861. doi: 10.1016/S1470-2045(14)70228-1
- Cheng H, Yang J, Liu H, et al. Poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis. Arch Gynecol Obstet. 2021;304(2):285–296. doi: 10.1007/s00404-021-06070-2
- Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107(10):1776–1782. doi: 10.1038/bjc.2012.451
- Pedersen BS, Konstantinopoulos PA, Spillman MA, et al. Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients. Genes Chromosomes Cancer. 2013;52(9):794–801. doi: 10.1002/gcc.22075
- Liu Y, Meng J, Wang G. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials. Drug Des Devel Ther. 2018;12:3013–3019. doi: 10.2147/DDDT.S164553
- Ruiz-Schutz VC, Gomes LM, Mariano RC, et al. Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: a meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2019;141:163–173. doi: 10.1016/j.critrevonc.2019.06.012
- Giannini A, Di Dio C, Di Donato V, et al. PARP inhibitors in newly diagnosed and recurrent ovarian cancer. Am J Clin Oncol [Internet]. 2023;46(9):414–419. [cited 2023 Dec 30]. Available from: https://pubmed.ncbi.nlm.nih.gov/37314974/